Monitor for NDA submission and potential conditional approval in China for first-line CLL/SLL, which would significantly expand lisaftoclax's commercial opportunity. Also watch for data readouts from the GLORA-2 global Phase III trial.
Price Chart
Executive Summary
Ascentage Pharma announced that its Bcl-2 inhibitor lisaftoclax (APG-2575) received Breakthrough Therapy Designation (BTD) from China's NMPA for treatment-naïve CLL/SLL in combination with acalabrutinib. This regulatory milestone could accelerate development and review timelines for a first-line indication, expanding the drug's addressable market beyond the already-approved relapsed/refractory setting.
Key Facts
- Lisaftoclax (APG-2575) granted Breakthrough Therapy Designation by China's CDE/NMPA for treatment-naïve CLL/SLL in combination with acalabrutinib.
- Lisaftoclax was already approved in China in July 2025 for relapsed/refractory CLL/SLL after BTK inhibitor therapy.
- BTD provides priority communication, development guidance, and potential for Priority Review and conditional NDA approval in China.
- The GLORA-2 global registrational Phase III trial is evaluating lisaftoclax + acalabrutinib as first-line CLL/SLL treatment.
- Lisaftoclax is the first China-developed Bcl-2 inhibitor approved in China and the second Bcl-2 inhibitor approved globally.
Financial Impact
No financial figures provided in the filing. The BTD could expand lisaftoclax's addressable patient population from relapsed/refractory to first-line CLL/SLL, potentially doubling or more the addressable market in China.
Risk Factors
- BTD does not guarantee eventual approval; clinical data must still support efficacy and safety.
- Competition from approved Bcl-2 inhibitors (venetoclax) and BTK inhibitors in first-line CLL/SLL.
- Lisaftoclax is not yet approved by the US FDA; global regulatory path remains uncertain.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-111393 |
| Document: ea030929901ex99-2.htm | 0001213900-26-111393 |
| Document: ea0309299-6k_ascentage.htm | 0001213900-26-111393 |
| Document: 0001213900-26-111393-index-headers.html | 0001213900-26-111393 |
| Document: 0001213900-26-111393-index.html | 0001213900-26-111393 |
| Document: 0001213900-26-111393.txt | 0001213900-26-111393 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $15.44 $15.45 | ▲ +0.06% | ▼ −0.65% | $14.67 (−4.99%) |
Oct 21, 2026 5d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $14.67 (−1.68%) |
Oct 15, 2026 12d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $14.67 (−0.14%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $14.67 (+4.55%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $14.67 (+15.30%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $14.67 (−12.96%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $14.67 (−12.70%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $14.67 (−22.34%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $14.67 (−20.14%) |
Jul 13, 2026 15w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $14.67 (−23.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers